![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
T Eissenberg, MK Greenwald, RE Johnson, IA Liebson, GE Bigelow and ML Stitzer
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Buprenorphine is a partial mu opioid agonist with demonstrated efficacy in the treatment of opioid dependence. One potential advantage of buprenorphine over full mu opioid agonists is its reported low physical dependence profile. This study systematically examined physical dependence produced by maintenance with a clinically relevant dose of buprenorphine using antagonist challenge procedures. In this residential laboratory study, eight opioid-dependent volunteers maintained on 8 mg/day of sublingual buprenorphine were each challenged on independent occasions with placebo, i.m. naloxone (0.3, 1.0, 3.0 and 10.0 mg/70 kg) and p.o. naltrexone (0.3, 1.0 and 3.0 mg/70 kg) 14 hr after their daily buprenorphine dose using a repeated measures, cross- over design. Both naloxone and naltrexone precipitated time- and dose- dependent withdrawal, as evidenced by changes in subject-rated, observer-rated and physiological measures. Significant precipitated withdrawal occurred at 3.0 and 10 mg/70 kg i.m. of naloxone and 3.0 mg/70 kg p.o. of naltrexone. These results indicate that buprenorphine maintenance produces physical dependence and that i.m. naloxone and p.o. naltrexone produce equivalent effects in withdrawal precipitation under these conditions. Findings have implications for selection of antagonist doses for use in formulating combination agonist/antagonist medications and for use in transition of drug abusers from buprenorphine to antagonist maintenance therapies.
This article has been cited by other articles:
|
|
 |
|
  M. C. H. Ko, M. F. Divin, H. Lee, J. H. Woods, and J. R. Traynor Differential in Vivo Potencies of Naltrexone and 6beta-Naltrexol in the Monkey J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 772 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Schottenfeld, M. C. Chawarski, J. R. Pakes, M. V. Pantalon, K. M. Carroll, and T. R. Kosten Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence Am J Psychiatry, February 1, 2005; 162(2): 340 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Sell, L. R. McMahon, and C. P. France Relative Efficacy of Buprenorphine, Nalbuphine and Morphine in Opioid-Treated Rhesus Monkeys Discriminating Naltrexone J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Holtzman Discrimination of a Single Dose of Morphine Followed by Naltrexone: Substitution of Other Agonists for Morphine and Other Antagonists for Naltrexone in a Rat Model of Acute Dependence J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Comer and E. D. Collins Self-Administration of Intravenous Buprenorphine and the Buprenorphine/Naloxone Combination by Recently Detoxified Heroin Abusers J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 695 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Robinson and M. J. Wallace Effect of Perinatal Buprenorphine Exposure on Development in the Rat J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 797 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Eissenberg, M. L. Stitzer, G. E. Bigelow, A. R. Buchhalter, and S. L. Walsh Relative Potency of levo-alpha -Acetylmethadol and Methadone in Humans under Acute Dosing Conditions J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 936 - 945. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. Houtsmuller, S. L. Walsh, K. J. Schuh, R. E. Johnson, M. L. Stitzer, and G. E. Bigelow Dose-Response Analysis of Opioid Cross-Tolerance and Withdrawal Suppression During LAAM Maintenance J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 387 - 396. [Abstract] [Full Text]
|
|
|
|
|
|
M. K. Greenwald, M. L. Stitzer, and K. A. Haberny J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1154 - 1163. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
